论文部分内容阅读
作者介绍了一种新的黄体生成素释放激素(LHRH)激动剂。ICI_(?)。治疗晚期前列腺癌的初步临床研究报告。8例患者均经组织学证实为前列腺癌,有或无转移.以前均未接受激素或细胞毒制剂治疗。每日上午10点皮下注射ICI_(?),4例每天用药250mg,持续3个月。另4例每天用药100mg。用药前和治疗的不同时间均采血测定睾酮.LH,FSH. 结果:治疗前。患者血浆睾酮的浓度全部在正常范围之内。每天注射250mgICI_(?)的4例。在治疗14天后患者血浆睾酮的浓度显著下降,并且在整个
The authors introduced a new luteinizing hormone-releasing hormone (LHRH) agonist. ICI_(?). Preliminary clinical studies for the treatment of advanced prostate cancer. All 8 patients were histologically proven to have prostate cancer with or without metastases. No previous treatment with hormones or cytotoxic agents was performed. ICU_(?) was subcutaneously injected daily at 10 o’clock in the morning; 4 cases were treated with 250 mg daily for 3 months. The other 4 patients used 100 mg daily. Testosterone, LH, and FSH were measured before and at different times of treatment. Results: Before treatment. The patient’s plasma testosterone concentration was all within the normal range. Four injections of 250 mg ICI_(?) were given daily. The plasma testosterone concentration dropped significantly after 14 days of treatment and